When the answer is “not available here.”

A family gets a sentence from a local hospital or pharmacy that sounds like a door closing. "This drug is not on our formulary." "This therapy is not approved here." "We cannot obtain this product." "The manufacturer does not sell this in our country." The sentence is usually delivered by someone who is trying to be helpful and who has correctly answered the question the family asked, within the scope of what that person can actually do. The sentence is not the end of the conversation. This page is about what happens after that sentence is said.

First, understand what was actually said

The exact phrasing of the answer matters. "Not on formulary" means the local institution has not included the drug in its standing inventory, which usually reflects a procurement or reimbursement decision rather than a regulatory one. "Not approved here" usually means the drug does not yet have a marketing authorization from the destination country's health authority, which is a different and more substantive issue. "Not available" is a catch-all that can mean either of the above, or can mean a temporary shortage, or can mean that the institution's pharmacy cannot source it through its usual channels. "The manufacturer does not sell this in our country" typically means the manufacturer has chosen not to register the product in the destination, often because the expected local market does not support the registration cost.

Before the family starts chasing an alternative, it is worth asking the person who delivered the sentence a clarifying question. Is this a formulary issue or an approval issue? Is it an availability issue? Is the answer different for a named-patient pathway? The clarifying question often produces a more useful picture, and sometimes reveals that the apparent "no" is actually a "not through this channel."

Who to call first: the prescriber

The treating physician is the correct first call after a local "no." Three reasons. First, the prescriber is the only person who can definitively say whether a locally-available alternative would serve the patient adequately. A sober second look at the local options, with the full clinical context, sometimes produces a path forward that the family would not have seen on their own. Second, the prescriber is the only person who can make the clinical case that a specific cross-border therapy is medically necessary for this specific patient; the named-patient pathway rests on that case. Third, the prescriber's judgment on whether to wait for local availability, to consider an alternative therapy, or to pursue a cross-border path is the judgment that should anchor the decision, not the family's research or a coordinator's enthusiasm.

A useful framing for the conversation with the prescriber is: if this therapy is the right therapy for this patient, are you willing to write the paperwork that a cross-border named-patient pathway would require? The question focuses the conversation on the clinical judgment first and on the logistics second. A prescriber who says yes has just opened a path that does not exist without the prescriber's engagement. A prescriber who says no, or who says "I would prefer we try X locally first," has given the family information that should change the next step.

Who to call second: a patient advocacy group

For most specialty indications, there is a patient advocacy organization that knows the landscape better than almost anyone else. For a rare-disease diagnosis, the disease-specific patient organization usually maintains a current map of where the therapy is available, how patients in other countries have accessed it, which coordinators have a track record for the indication, and what the manufacturer's own global-access program offers. For an oncology diagnosis, the indication-specific patient group or a broader cancer-patient organization can play the same role. The advocacy group is typically free to consult, independent of any commercial interest, and oriented to what works for patients rather than to what a coordinator would prefer.

A family that has spent an hour on the phone with a good patient advocacy group often arrives at a cross-border coordinator better prepared than a family that has gone directly to the coordinator. The advocacy group tends to ask the right questions and to surface the right options, and the family ends up with a sharper picture of what the coordinator is actually being asked to do.

Who to call third: an NPP coordinator

When the prescriber is engaged and the advocacy group has confirmed that the cross-border path is viable for the indication, the next call is to a named-patient program coordinator. This is where we and our peer organizations come in. The coordinator's role, at this stage, is to confirm that the specific drug-destination combination is workable under a named-patient pathway, to quote the case on a line-item basis, and to carry the regulatory and logistics load across the weeks that follow. A good coordinator will tell a family quickly whether the case is one they can take; a coordinator that will not give a candid feasibility signal at intake is one to be cautious about.

For families considering us specifically, the self-screening walkthrough is a good starting point, and the comparison page is where we set out honestly how we differ from the best-known peer in the category. We would rather a family arrive at us after a considered comparison than after a marketing-driven rush.

Practical steps for the family

There is a short sequence that almost always serves a family whose local answer was "no." First, document the local answer in writing. A short email from the institution's pharmacy, confirming the formulary or availability position, is useful for the named-patient application at destination, because destination regulators typically want evidence that locally-available alternatives have been considered. Second, secure a written plan from the treating prescriber that identifies the therapy being recommended, the indication, and the clinical rationale. Third, speak to the relevant patient advocacy organization and note the specific recommendations they offer. Fourth, contact a coordinator to get a case-specific feasibility signal and a line-item cost envelope. Fifth, evaluate the whole picture before committing, and take the weekend to do it. The weekend does not cost the case; rushing often does.

What to do if the prescriber is uncertain

Some prescribers are enthusiastic about cross-border pathways; others are cautious. Caution is usually reasonable. A prescriber who has not worked across borders before may hesitate to take on documentation they do not fully understand, to sign a medical-necessity letter whose downstream use they cannot fully see, or to accept the adverse-event reporting that flows back to them. Those are legitimate concerns, and the right response from the family is not to pressure the prescriber; it is to share credible information about what the pathway actually asks of them. We have written the prescribing across borders guide specifically for this purpose. A family can share the guide with the prescriber, and the prescriber can decide on their own terms.

If the prescriber remains uncertain, a second-opinion consultation with a specialist at a tertiary medical center that does have cross-border experience is sometimes the right next step. The tertiary-center specialist can carry more of the clinical case than the local prescriber, and can either write the paperwork directly or partner with the local prescriber on the documentation.

What to do if the destination country is the obstacle

Sometimes the obstacle is the destination country rather than the local institution. The destination's named-patient pathway may be closed for the indication, or the timeline may be incompatible with the clinical urgency, or the specific drug-indication combination may sit outside what the destination will authorize. A good coordinator will tell the family this at intake. When it happens, the conversation turns to alternatives: a different therapy that is locally accessible, a different destination for the named-patient application if the patient can travel, the manufacturer's global-access program, or a specialty-tier treatment abroad through medical travel rather than cross-border import. Each of those is a different set of trade-offs, and each is a distinct conversation with a different set of advisors. None of them is a reason to despair, but they are reasons to widen the lens.

What the family should not do

Do not buy medicine from an online source that the treating physician has not approved. Do not wire money to a coordinator the family cannot verify. Do not discontinue locally-prescribed therapy on the strength of a hoped-for cross-border therapy until the cross-border therapy is confirmed, paid, and en route. Do not assume that a high-profile news article about a new therapy means the therapy is accessible; access and approval are often separated by months or years. Do not let urgency collapse the decision framework the family would otherwise use for a major financial commitment. The weight of the diagnosis is real; the way through it is still careful steps.

A closing note

"Not available here" is not the end. It is usually the beginning of a different conversation, one that involves the prescriber more centrally, a patient advocacy organization more practically, and a named-patient coordinator more specifically than the local hospital pharmacy was ever in a position to have. Families who walk through the sequence in that order tend to arrive at a workable answer. The work takes weeks, not hours, and the weeks are rarely wasted. When the family is ready to begin the coordinator conversation with us, the consultation page is the entry point, and the when we decline, and why page is the honest account of what we will and will not take on.

Reviewed 2026-04-22 by Reserve Meds’s AI clinical and regulatory review agents. Human pharmacist-in-charge: Altima Care. Next scheduled review: 2026-10-22.